Last Updated: May 10, 2026

Suppliers and packagers for ATOMOXETINE HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


ATOMOXETINE HYDROCHLORIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Apotex ATOMOXETINE HYDROCHLORIDE atomoxetine hydrochloride CAPSULE;ORAL 078983 ANDA A-S Medication Solutions 50090-4236-0 30 CAPSULE in 1 BOTTLE (50090-4236-0) 2018-05-21
Apotex ATOMOXETINE HYDROCHLORIDE atomoxetine hydrochloride CAPSULE;ORAL 078983 ANDA AvPAK 50268-057-13 30 BLISTER PACK in 1 BOX (50268-057-13) / 1 CAPSULE in 1 BLISTER PACK (50268-057-11) 2020-02-13
Apotex ATOMOXETINE HYDROCHLORIDE atomoxetine hydrochloride CAPSULE;ORAL 078983 ANDA AvPAK 50268-058-13 30 BLISTER PACK in 1 BOX (50268-058-13) / 1 CAPSULE in 1 BLISTER PACK (50268-058-11) 2020-02-13
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

ATOMOXETINE HYDROCHLORIDE: Supplier Landscape for Active Ingredient (API) and Key Intermediates

Last updated: April 23, 2026

Which companies supply atomoxetine hydrochloride API?

The atomoxetine hydrochloride supply chain is concentrated in a small set of multinational and specialty generics/CRO-adjacent manufacturers that produce the API and provide documentation packages aligned with pharmaceutical regulatory needs.

Primary API supply categories

Supply segment What it sells Typical buyer
API manufacturers Atomoxetine hydrochloride API (controlled particle size specs and assay specs) Generics developers, branded packagers, pharma manufacturers
Contract manufacturers (API/CMP) Atomoxetine hydrochloride API plus development and manufacturing support Companies without internal API capacity
Intermediates suppliers Key building blocks and intermediates used to synthesize the API API manufacturers, custom synthesis providers

Known active suppliers (company-level)

Supplier Role in supply chain Evidence type
SMTIL (SMT India) Atomoxetine hydrochloride API / generic-grade supply Public product and distribution listings
Shaanxi New Leading Pharmaceutical Technology Atomoxetine hydrochloride supply for research/manufacturing Public product catalog listings
Hangzhou Zhongqi Pharmaceutical Atomoxetine hydrochloride supply Public product listings
Alfa Chemistry Atomoxetine hydrochloride (marketed for research and procurement channels) Public marketplace listing
AmiChem / AmiChem (China-based chemical supplier channel) Atomoxetine hydrochloride supply Public marketplace listing

Operational note for procurement: atomoxetine hydrochloride is sold through both regulatory-grade supply channels and “chemical procurement” channels. For commercial production, buyers generally require a vendor qualification pack (GMP certificate, COA, impurity profile, change control history, and supply continuity terms).

Which countries dominate API manufacturing for atomoxetine hydrochloride?

Atomoxetine hydrochloride API supply is concentrated in established chemical-manufacturing hubs with mature contract manufacturing ecosystems.

Dominant manufacturing geography Typical supplier profile
India Generic API manufacturers and contract API suppliers
China Specialty chemical and API intermediate ecosystems feeding final API production
EU/US-adjacent supply Smaller share of direct API supply; more involved in advanced intermediates, formulations, or regulatory services

Who supplies atomoxetine hydrochloride intermediates used for API synthesis?

Atomoxetine hydrochloride is synthesized through commercially available substituted heterocycle and amine-building blocks. Intermediate procurement is typically handled by the same manufacturers that supply the final API or by specialty chemical suppliers that sell those intermediates.

Common intermediate sourcing pattern

Intermediate class Typical sourcing route Buyer impact
Substituted aromatic/heteroaromatic precursors Specialty chemical suppliers (multi-purpose catalogs) or custom synth Impacts impurity profile and control strategy
Amine/amine-protection and deprotection reagents Bulk chemical suppliers Impacts batch-to-batch impurity consistency
Salt formation inputs (HCl source) Bulk reagent suppliers Impacts salt stoichiometry and residual solvents

Procurement best practice for intermediates: intermediate vendors generally supply with limited impurity characterization unless the intermediate is sold for GMP use. For GMP API production, the intermediate supplier selection often hinges on impurity carryover risk and documentation availability.

What documentation and qualification items procurement teams require from suppliers?

Even when vendors advertise availability, commercial buyers typically require a standardized “qualification pack.” Below is the minimum documentation set typically needed for safe API supply decisions for a marketed product or clinical/commercial scale manufacturing.

Typical supplier documentation package

  • GMP compliance: GMP certificate covering API manufacturing site(s)
  • Batch documentation: COA for representative lots
  • Quality agreement: scope, change notification, deviation handling, and specification ownership
  • Impurity profile: identified and unidentified impurities with limits
  • Stability data: retest period support
  • Regulatory history: DMF/CEP linkage when applicable
  • Supply continuity: manufacturing capacity confirmation and lead-time commitments

How to compare suppliers quickly for atomoxetine hydrochloride readiness

Procurement teams usually need a short scorecard before engaging in a full quality audit.

Supplier comparison scorecard

Dimension What to check Why it matters
Regulatory grade availability GMP site coverage and documentation completeness Prevents qualification delays
Impurity control Limits alignment and impurity identification capability Reduces rejection risk
Manufacturing capacity Confirmed annual tonnage and batch frequency Ensures continuity
Change control Documented process and formulation/route change policy Controls regulatory drift
Technical support Ability to support method transfer and scale-up Speeds qualification

Supply chain risk points specific to atomoxetine hydrochloride

Atomoxetine hydrochloride supply decisions often fail on operational details rather than on molecule availability.

  • Salt form consistency: supplier variability in HCl concentration, crystal habit, and drying endpoint can shift downstream handling parameters.
  • Impurity carryover: intermediate impurity profiles transfer into API impurity profiles; buyers need a transparent impurity control story.
  • Reagent and solvent residuals: solvents and drying conditions drive residual solvent and water content specs, especially for finished material handling.
  • Lead-time and batch scheduling: API manufacturing is batch-locked; continuity requires confirmed capacity and locked slots.

Key Takeaways

  • Atomoxetine hydrochloride API supply is available through multiple specialized chemical and API procurement channels, with the strongest density in India and China.
  • For commercial-grade use, buyers should restrict vendor onboarding to suppliers that can produce a full GMP documentation package, not just a catalog COA.
  • The fastest procurement path usually comes from suppliers that already provide impurity profile support, stability/retest data, and change control history aligned with pharma qualification workflows.
  • Intermediate supply is often handled through the same manufacturing ecosystem; intermediate impurity carryover is the dominant quality risk driver.

FAQs

1) Can atomoxetine hydrochloride be sourced from “research chemical” suppliers?

It can, but those channels often lack GMP-site documentation and impurity controls required for commercial API qualification.

2) What matters most when qualifying a new atomoxetine hydrochloride API supplier?

Impurity profile alignment, GMP documentation, and batch-to-batch consistency (including residual solvents and salt form attributes).

3) Does supplier geography determine quality for atomoxetine hydrochloride?

No single geography guarantees quality, but procurement diligence and documentation depth typically correlate with established GMP API ecosystems.

4) Are intermediates always supplied with full impurity disclosure?

Not universally. For GMP API production, buyers should verify intermediate impurity characterization and its linkage to the API control strategy.

5) What is the procurement bottleneck for atomoxetine hydrochloride supply?

Quality qualification and documentation completeness, followed by confirmed manufacturing capacity and continuity scheduling.


References

[1] Alfa Chemistry. “Atomoxetine Hydrochloride.” Alfa Chemistry product listing.
[2] Hangzhou Zhongqi Pharmaceutical. “Atomoxetine Hydrochloride” product listing.
[3] AmiChem. “Atomoxetine Hydrochloride” product listing.
[4] SMTIL (SMT India). “Atomoxetine Hydrochloride” product/distribution listing.
[5] Shaanxi New Leading Pharmaceutical Technology. “Atomoxetine Hydrochloride” product listing.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.